Table 1 Characteristics of the studies included in the meta-analysis
Author | Year | Method | Country | Participants | Intervention(s) | Outcomes | |
|---|---|---|---|---|---|---|---|
Control | Placebo | ||||||
NINDS [22] | 2006 | RCT | USA | 67 | 67 | Creatine 10 g/d and Minocycline 200 mg/d | Total UPDRS scores; UPDRS I/II/III |
Bender [21] | 2006 | RCT | Germany | 40 | 20 | Creatine 4 g/d | Total UPDRS scores; UPDRS I/II/III |
NINDS [20] | 2008 | RCT | USA | 64 | 63 | Creatine 10 g/d | Total UPDRS scores; |
Kieburtz [19] | 2015 | RCT | Canada USA | 477 | 478 | Creatine 10 g/d | Total UPDRS scores; UPDRS I/II/III Schwab & England Scale |
Li [18] | 2015 | RCT | China | 38 | 37 | Creatine 10 g/d and Coenzyme Q10 300 mg/d | UPDRS III Schwab & England Scale |